Literature DB >> 25757565

Amyloid β peptide directly impairs pineal gland melatonin synthesis and melatonin receptor signaling through the ERK pathway.

Erika Cecon1, Min Chen1, Marina Marçola1, Pedro A C Fernandes1, Ralf Jockers1, Regina P Markus2.   

Abstract

Melatonin is the hormone produced by the pineal gland known to regulate physiologic rhythms and to display immunomodulatory and neuroprotective properties. It has been reported that Alzheimer disease patients show impaired melatonin production and altered expression of the 2 G protein-coupled melatonin receptors (MTRs), MT₁ and MT₂, but the underlying mechanisms are not known. Here we evaluated whether this dysfunction of the melatonergic system is directly caused by amyloid β peptides (Aβ(1-40) and Aβ(1-42)). Aβ treatment of rat pineal glands elicited an inflammatory response within the gland, evidenced by the up-regulation of 52 inflammatory genes, and decreased the production of melatonin up to 75% compared to vehicle-treated glands. Blocking NF-κB activity prevented this effect. Exposure of HEK293 cells stably expressing recombinant MT₁ or MT₂ receptors to Aβ lead to a 40% reduction in [(125)I]iodomelatonin binding to MT₁. ERK1/2 activation triggered by MTRs, but not by the β₂-adrenergic receptor, was markedly impaired by Aβ in HEK293 transfected cells, as well as in primary rat endothelial cells expressing endogenous MTRs. Our data reveal the melatonergic system as a new target of Aβ, opening new perspectives to Alzheimer disease diagnosis and therapeutic intervention. © FASEB.

Entities:  

Keywords:  Alzheimer disease; nuclear factor κB

Mesh:

Substances:

Year:  2015        PMID: 25757565     DOI: 10.1096/fj.14-265678

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  19 in total

Review 1.  Update on melatonin receptors: IUPHAR Review 20.

Authors:  Ralf Jockers; Philippe Delagrange; Margarita L Dubocovich; Regina P Markus; Nicolas Renault; Gianluca Tosini; Erika Cecon; Darius P Zlotos
Journal:  Br J Pharmacol       Date:  2016-08-08       Impact factor: 8.739

2.  Phosphoinositides: Two-Path Signaling in Neuronal Response to Oligomeric Amyloid β Peptide.

Authors:  Romina María Uranga; Natalia Paola Alza; Melisa Ailén Conde; Silvia Susana Antollini; Gabriela Alejandra Salvador
Journal:  Mol Neurobiol       Date:  2016-04-14       Impact factor: 5.590

3.  Design and validation of the first cell-impermeant melatonin receptor agonist.

Authors:  Florence Gbahou; Erika Cecon; Guillaume Viault; Romain Gerbier; Frederic Jean-Alphonse; Angeliki Karamitri; Gérald Guillaumet; Philippe Delagrange; Robert M Friedlander; Jean-Pierre Vilardaga; Franck Suzenet; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-06-11       Impact factor: 8.739

4.  Quantitative assessment of oligomeric amyloid β peptide binding to α7 nicotinic receptor.

Authors:  Erika Cecon; Julie Dam; Marine Luka; Clément Gautier; Anne-Marie Chollet; Philippe Delagrange; Laurence Danober; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2019-05-20       Impact factor: 8.739

5.  Functional Investigation of Melatonin Receptor Activation by Homogenous cAMP Assay.

Authors:  Erika Cecon; Jean-Luc Guillaume; Ralf Jockers
Journal:  Methods Mol Biol       Date:  2022

6.  Importance of the second extracellular loop for melatonin MT1 receptor function and absence of melatonin binding in GPR50.

Authors:  Nathalie Clement; Nicolas Renault; Jean-Luc Guillaume; Erika Cecon; Anne-Sophie Journé; Xavier Laurent; Kenjiro Tadagaki; Francis Cogé; Arnaud Gohier; Philippe Delagrange; Philippe Chavatte; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2017-10-27       Impact factor: 8.739

Review 7.  Immune-pineal axis - acute inflammatory responses coordinate melatonin synthesis by pinealocytes and phagocytes.

Authors:  Regina P Markus; Pedro A Fernandes; Gabriela S Kinker; Sanseray da Silveira Cruz-Machado; Marina Marçola
Journal:  Br J Pharmacol       Date:  2017-12-15       Impact factor: 8.739

8.  Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure.

Authors:  Abla Benleulmi-Chaachoua; Alan Hegron; Marine Le Boulch; Angeliki Karamitri; Marta Wierzbicka; Victoria Wong; Igor Stagljar; Philippe Delagrange; Raise Ahmad; Ralf Jockers
Journal:  Cell Mol Life Sci       Date:  2018-07-24       Impact factor: 9.261

9.  Orphan GPR61, GPR62 and GPR135 receptors and the melatonin MT2 receptor reciprocally modulate their signaling functions.

Authors:  Atsuro Oishi; Angeliki Karamitri; Romain Gerbier; Olivier Lahuna; Raise Ahmad; Ralf Jockers
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

Review 10.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.